Facebook Pixel
The Lancet Respiratory Medicine in conversation with

Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.

Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

The Lancet Respiratory Medicine in conversation with
Not playing